Nifedipina Doc Generici (Nifedipine)

Nifedipine, the active ingredient in Nifedipina Doc Generici, is a calcium channel blocker presented as an oral dosage form for oral use. It is employed to lower high blood pressure, relieve chest pain from angina, and improve blood flow in Raynaud's phenomenon, primarily in adult patients. GNH USA supplies Nifedipina Doc Generici as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nifedipine belongs to the calcium channel blocker class and is indicated for several cardiovascular conditions.

Hypertension: lowers systemic blood pressure by relaxing arterial smooth muscle. Angina pectoris: reduces myocardial oxygen demand through coronary vasodilation. Raynaud's phenomenon: improves peripheral blood flow by preventing vasospasm.

Nifedipine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: warm sensation, often transient. - Peripheral edema: swelling of ankles or feet. - Dizziness or light‑headedness. - Tachycardia: increased heart rate. - Nausea or abdominal discomfort.

Serious or Rare Side Effects: - Severe hypotension: sudden, marked drop in blood pressure. - Myocardial infarction: rare but possible in high‑risk patients. - Atrial fibrillation or other arrhythmias. - Hepatic dysfunction: elevated liver enzymes. - Severe allergic reactions: rash, swelling, anaphylaxis. - Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating therapy, consider the following safety measures.

Blood pressure monitoring: ensure baseline and periodic checks. Cardiovascular disease: evaluate for heart failure or recent myocardial infarction. Liver impairment: dose adjustment may be required. Elderly patients: start with lower doses due to altered pharmacokinetics. Drug interactions: review concomitant medications for CYP3A4 substrates or inhibitors. Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Nifedipine can interact with several drug classes; some require avoidance while others need close monitoring.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise nifedipine levels. - Co‑administration with other antihypertensives: risk of additive hypotension. - Grapefruit juice: enhances oral absorption, increasing exposure.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Beta‑blockers: may mask tachycardia, requiring heart‑rate monitoring. - Diuretics: can amplify electrolyte disturbances and volume depletion.